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Identiﬁcation of nine new susceptibility loci
for endometrial cancer
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Endometrial cancer is the most commonly diagnosed cancer of the female reproductive tract
in developed countries. Through genome-wide association studies (GWAS), we have pre-
viously identiﬁed eight risk loci for endometrial cancer. Here, we present an expanded meta-
analysis of 12,906 endometrial cancer cases and 108,979 controls (including new genotype
data for 5624 cases) and identify nine novel genome-wide signiﬁcant loci, including a locus
on 12q24.12 previously identiﬁed by meta-GWAS of endometrial and colorectal cancer. At
ﬁve loci, expression quantitative trait locus (eQTL) analyses identify candidate causal genes;
risk alleles at two of these loci associate with decreased expression of genes, which encode
negative regulators of oncogenic signal transduction proteins (SH2B3 (12q24.12) and NF1
(17q11.2)). In summary, this study has doubled the number of known endometrial cancer risk
loci and revealed candidate causal genes for future study.
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Endometrial cancer accounts for ~7% of new cancer cases inwomen1 and is the most common invasive gynecologicalcancer in developed countries (http://gco.iarc.fr/today/
home). Risk of endometrial cancer is approximately double for
women who have a ﬁrst degree relative with endometrial
cancer2,3. Rare high-risk pathogenic variants in mismatch-repair
genes, PTEN, and DNA polymerase genes4 explain a small pro-
portion of endometrial cancers, and the eight previously pub-
lished common endometrial cancer-associated single-nucleotide
polymorphisms (SNPs) identiﬁed by genome-wide association
studies (GWAS) studies5–8 together explain <5% of the familial
relative risk (FRR).
Here, we conduct a meta-GWAS including 12,906 endometrial
cancer cases and 108,979 country-matched controls of European
ancestry from 17 studies identiﬁed via the Endometrial Cancer
Association Consortium (ECAC), the Epidemiology of Endo-
metrial Cancer Consortium (E2C2) and the UK Biobank and
report a further nine genome-wide signiﬁcant endometrial cancer
genetic risk regions. One of these risk regions on 12q24.12 was
previously identiﬁed by meta-GWAS of endometrial and color-
ectal cancer9. eQTL and gene network analyses reveal candidate
causal genes and pathways relevant for endometrial
carcinogenesis.
Results
GWAS meta-analysis. Details of genotyping for each study are
found in Supplementary Data 1 and individual studies described
in the Supplementary Information. Following standard quality
control (QC) for each dataset (Supplementary Methods), geno-
types were imputed using the 1000 Genomes Project v3 reference
panel (combined with the UK10K reference panel for the WHI
and UK Biobank studies). SNP-disease associations in each study
were tested using logistic regression, adjusting for principal
components, and risk estimates were combined using inverse-
variance weighted ﬁxed-effects meta-analysis. We found little
evidence of genomic inﬂation in any dataset (λ1000=
0.996–1.128) or overall (λ1000= 1.004) (Supplementary Fig. 1).
Using linkage disequalibrium (LD) score regression, we estimate
that 93% of the observed test statistic inﬂation is due to polygenic
signal, as opposed to population stratiﬁcation.
Seven of the eight published genome-wide signiﬁcant endo-
metrial cancer loci were conﬁrmed with increased signiﬁcance
(Table 1, Fig. 1a), although the effect sizes for some loci were
slightly attenuated compared with our previous analysis (com-
prising 7737 cases and 37,144 controls7, all also included in the
current analysis). For example, the most signiﬁcant SNP in this
meta-analysis, rs11263761 intronic in HNF1B, had an odds ratio
(OR)= 1.15 (1.12–1.19; P= 3.2 × 10−20), compared with OR=
1.20 (1.15–1.25; P= 2.8 × 10−19) in our previous analysis7. The
previously reported associations with intronic AKT1 SNPs
(rs2498796 OR= 1.17 (1.07–1.17); P= 3.6 × 10−8)6,10 did not
reach genome-wide signiﬁcance (rs2498796 OR= 1.07
(1.03–1.11) P= 6.3 × 10−5, Bayes false discovery probability
(BFDP) 98%) in this meta-analysis, although the risk estimate
direction is consistent with our original ﬁnding.
Excluding the 500 kb, either side of the risk loci previously
reported at genome-wide signiﬁcance for endometrial cancer
alone, we found 125 SNPs with P < 5 × 10−8. Using approximate
conditional association testing with GCTA software11, these were
resolved into nine independent risk loci; eight newly reported
regions, plus the 12q24.12 locus previously identiﬁed by a joint
endometrial-colorectal cancer analysis9 (Table 2, Fig. 1b,
Fig. 2a–i). The BFDP was ≤4% for all nine novel loci. The
analysis was repeated with the restricted set of 8758 cases with
endometrioid cancer, the most common histology (Fig. 1c); this
identiﬁed one additional variant at 7p14.3 reaching genome-wide
signiﬁcance (rs9639594; Supplementary Data 2). However, given
the sparse LD at this region and the fact that this is a single,
imputed variant, further investigation of this region is required to
conﬁrm its association with endometrial cancer risk. No SNP
reached genome-wide signiﬁcance in an analysis restricted to the
1230 non-endometrioid cases (Fig. 1d) or in separate analyses of
carcinosarcomas, serous, clear cell or mucinous carcinomas, for
which statistical power is very limited (Supplementary Data 2,
Supplementary Fig. 2).
For these nine newly reported endometrial cancer loci, a
statistically signiﬁcant difference in risk estimates by histolo-
gical subgroup was observed only for the 2p16.1 locus; the risk
was higher for non-endometrioid than for endometrioid cancer
(rs148261157 OR= 1.64 (1.32–2.04) and OR= 1.25
(1.14–1.38), respectively, case-only Pf= 0.003, Table 2).
Table 1 Meta-analysis results for previously identiﬁed genome-wide signiﬁcant endometrial cancer risk loci
Region SNP Position
(bp)a
Nearby
gene(s)
Effect:
other
alleles
EAF Info All histologies (12,906 cases;
108,979 controls)
Endometrioid histology
(8758 cases; 46,126
controls)
Non-endometrioid histologies
(1230 cases; 35,447 controls)
Between
histologies
Allelic OR
(95% CI)
P I2 BFDP
(%)
Allelic OR
(95% CI)
P I2 Allelic OR
(95% CI)
P I2 P
6p22.3 rs1740828 21,648,854 SOX4 G:A 0.52 G 1.15 (1.11,
1.19)
4.2E
−16
25% <1% 1.16 (1.11,
1.20)
6.0E
−13
11% 1.00 (0.91,
1.10)
9.81.4E-
01E−01
7% 0.016
6q22.31 rs2747716 125,687,226 HEY2,
NCOA7
A:G 0.57 1.00 1.10 (1.07,
1.14)
2.9E
−10
55% <1% 1.12 (1.08,
1.16)
4.4E
−10
36% 0.99 (0.91,
1.08)
7.9E−01 0% 0.058
8q24.21b rs35286446 128,433,617 MYC GAT:G 0.58 0.99 1.10 (1.06,
1.13)
3.1E
−09
0% <1% 1.10 (1.06,
1.14)
1.8E
−07
0% 1.10 (1.01,
1.19)
3.6E
−02
0% 0.83
8q24.21b rs4733613 128,587,032 MYC C:G 0.12 G 1.18 (1.13,
1.24)
7.5E
−14
0% <1% 1.21 (1.15,
1.28)
1.2E
−13
0% 1.08 (0.95,
1.22)
2.3E−01 0% 0.041
8q24.21b rs139584729 128,611,656 MYC C:G 0.98 0.97 1.40 (1.25,
1.58)
2.4E
−08
0% 2% 1.48 (1.28,
1.70)
7.6E
−08
0% 1.18 (0.86,
1.63)
3.0E−01 0% 0.24
13q22.1 rs7981863 73,238,004 KLF5,
KLF12
C:T 0.72 G 1.16 (1.12,
1.20)
2.7E
−17
26% <1% 1.17 (1.13,
1.22)
4.9E
−15
0% 1.13 (1.02,
1.24)
1.4E−02 45% 0.95
14q32.33c rs2498796 104,776,883 AKT1 A:G 0.30 0.98 1.07 (1.03,
1.11)
6.3E
−05
1% 98% 1.09 (1.04,
1.13)
3.2E
−05
0% 1.07 (0.98,
1.17)
1.4E−01 11% 0.69
15q15.1 rs937213 40,029,923 EIF2AK4,
BMF
C:T 0.42 G 1.09 (1.06,
1.13)
5.1E
−09
0% 1% 1.12 (1.08,
1.16)
6.9E
−10
0% 1.15 (1.06,
1.25)
1.0E−03 12% 0.78
15q21.2 rs17601876 51,261,712 CYP19A1 G:A 0.48 1.00 1.12 (1.09,
1.16)
3.3E
−14
0% <1% 1.12 (1.08,
1.16)
2.3E
−10
0% 1.05 (0.96,
1.14)
3.0E−01 35% 0.02
17q12 rs11263761 37,737,784 HNF1B A:G 0.52 0.98 1.15 (1.12,
1.19)
3.2E
−20
25% <1% 1.15 (1.11,
1.19)
3.4E
−14
14% 1.20 (1.10,
1.31)
3.6E
−05
2% 0.70
EAF: effect allele frequency among control subjects in the UK Biobank, Info: imputation quality score for the OncoArray set, G: genotyped SNPs, I2: heterogeneity I2 statistic, BFDP: Bayes false discovery46
aPosition is with reference to build 38 of the reference genome
bResults for the 8q24 SNPs are from the conditional model containing all three SNPs. r2= 0.02 for rs35286446 and rs4733613; r2= 0.01 for rs35286446 and rs139584729; r2= 0.003 for rs4733613
and rs139584729
crs2498796 (14q32.33) was not replicated in this analysis
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There was no evidence of secondary signals at any of these nine
loci after conditioning on the most signiﬁcant variant. There
was no signiﬁcant between-study heterogeneity (minimum
Cochran Q-test Phet= 0.04, maximum I2= 41%, Supplemen-
tary Fig. 3), and random-effects meta-analyses produced
very similar results (Supplementary Data 2). Twenty-ﬁve
additional independent loci showed moderately signiﬁcant
(P < 1 × 10−6) associations, nine with endometrial cancer over-
all, nine speciﬁcally with endometrioid histology, and seven
with non-endometrioid histology (Supplementary Data 2).
Overlap with published GWAS associations. Using a 100:1
likelihood ratio, “credible causal risk” variants (ccrSNPs) were
compiled for each of the nine new endometrial cancer risk loci
(Supplementary Data 3). These included 239 variants located in
non-coding regions, 2 missense variants (rs2278868 SKAP1
Gly161Ser and rs3184504 SH2B3 Trp262Arg), and 1 synon-
ymous variant (rs1129506 EVI2A Ser23Ser). Comparing to the
NHGRI-EBI catalog of published GWAS, 37 SNPs previously
associated with a cancer, hormonal trait, or anthropometric
trait fall within 500 kb of any one of the novel endometrial
cancer SNPs. However, the only overlap from the set of
ccrSNPs with other traits was the colorectal and endometrial
cancer susceptibility SNP rs3184504 in SH2B3 (Supplementary
Data 4).
eQTL analyses. LD score regression analyses using eQTL results
from GTEx12 showed that endometrial cancer heritability
exhibited the strongest evidence for enrichment for variants
associated with genes speciﬁcally expressed in vaginal and uterine
tissue, in line with prior assumptions, although none of the tissue-
speciﬁc enrichments were signiﬁcant (weighted regression with
jackknife standard errors) after Bonferroni correction, adjusting
for the number of tissues tested (Supplementary Fig. 4). eQTL
analyses were performed using data from a variety of tissue
sources (Supplementary Methods), including endometrial tumor
and adjacent normal endometrium tissue from The Cancer
Genome Atlas (TCGA)13, normal cycling endometrium14 and, in
view of the GTEx enrichment results, vaginal and uterine tissue.
Additionally, we assessed eQTLs from whole blood15, which
provided substantially increased power over solid tissue analyses
due to increased sample size. eQTLs were detected at ﬁve of the
nine novel loci (Supplementary Data 3, Supplementary Data 5,
Supplementary Figs. 5–13, Table 2).
Gene network analysis. Network analysis was performed using
candidate causal genes identiﬁed in this study, in addition to
candidate causal genes identiﬁed in previous studies6–8 (Supple-
mentary Data 6). One major network was identiﬁed, containing
18 of the 25 candidate causal genes (Supplementary Fig. 14).
Network hubs included CCND1, CTNNB1, and P53, which are
encoded by genes that are somatically mutated in endometrial
cancer13. Analysis of the network revealed signiﬁcant enrichment
(Benjamini–Hochberg adjusted P < 0.05, hypergeometric test) in
relevant pathways such as endometrial cancer signaling, adipo-
genesis, Wnt/β-catenin signaling, estrogen-mediated S-phase
entry, P53 signaling, and PI3K/AKT signaling (Supplementary
Data 7).
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Fig. 1 Manhattan plot of the results of the endometrial cancer meta-analysis of 12,906 cases and 108,979 controls. Genetic variants are plotted according
to chromosome and position (x axis) and statistical signiﬁcance (y axis). The red line marks the 5 × 10−8 GWAS signiﬁcance threshold. a Endometrial
cancer (all histologies). b Endometrial cancer (all histologies) excluding variants within 500 kb of previously published endometrial cancer variants.
c Endometrioid histology endometrial cancer excluding variants within 500 kb of previously published endometrial cancer variants. d Non-endometrioid
histology endometrial cancer
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Functional annotation of ccrSNPs. Next, ccrSNPs were mapped
to epigenomic features from endometrial cancer cell lines (Sup-
plementary Data 3, Supplementary Figs. 5–13). Chromatin
immunoprecipitation (ChIP-seq) was used to map histone
modiﬁcations indicative of promoters or enhancers (H3K4Me1,
H3K4Me3, and H3K27Ac) in two endometrial cancer cell lines
(Ishikawa and JHUEM-14). Mapping of DNaseI hypersensitivity
sites (indicative of open chromatin) and ChIP-seq data for
transcription factor binding sites from Ishikawa cells were
accessed from ENCODE16. We also included mapping of
H3K427Ac histone modiﬁcations for uterus and vagina from
ENCODE. Overall, 73% of ccrSNPs overlapped at least one epi-
genomic feature, including at least one ccrSNP per novel risk
region. This overlap was signiﬁcantly greater than the overlap
observed for these epigenomic features with ccrSNPs related to,
for example, endometriosis17 (51%; Fisher’s exact P= 8.7 × 10−8)
or schizophrenia18 (40%; Fisher’s exact P < 2.2 × 10−16). These
ﬁndings indicate the relevance of the selected cell and tissue types
for informing endometrial cancer biology and a role for the
assessed epigenomic features in regulatory processes related to the
ccrSNPs. Overlaps between ccrSNPs and epigenomic features
increased signiﬁcantly after stimulation with estrogen (50% ver-
sus 38% for unstimulated features; Fisher’s exact P= 5.6 × 10−3),
emphasizing the importance of estrogen in endometrial cancer
etiology.
Mendelian randomization analyses. This expanded meta-
analysis allowed us to strengthen our previous Mendelian ran-
domization ﬁndings19,20 that higher body mass index (BMI)
(P= 1.7 × 10−11, two-sample inverse-variance weighted Mende-
lian randomization (MR) test), but not waist:hip ratio (P= 0.71),
is causal for endometrial cancer (Table 3) and that the protective
effect of later menarche on endometrial cancer risk (OR= 0.82,
95% CI 0.77–0.87 per year of delayed menarche, P= 2.2 × 10−9)
is partially mediated by the known relationship between lower
BMI and later menarche, with a more modest protective effect of
later menarche after adjusting for genetically predicted BMI
(OR= 0.88, 95% CI 0.82–0.94, P= 3.8 × 10−4). The association
between genetically predicted age at natural menopause and
endometrial cancer did not reach statistical signiﬁcance (OR=
1.03, 95% CI 1.00–1.06, P= 0.060). In contrast to the reported
effects for breast and prostate cancer21,22, we found no evidence
that genetically predicted adult height is associated with endo-
metrial cancer (P= 0.90).
Genetic correlation analyses. Cross-trait LD score regression of
224 non-cancer traits available via the LD Hub interface23,
identiﬁed signiﬁcant genetic correlations between endometrial
cancer and 14 traits. All of these are either a measure of obesity or
are strongly and signiﬁcantly (correlation-corrected jackknife P <
10−12) genetically correlated with BMI (i.e., age of menarche, type
2 diabetes, and years of schooling) (Supplementary Data 8), in
line with the established relationship between obesity and endo-
metrial cancer risk.
Discussion
In the largest GWAS meta-analysis assessing endometrial cancer
risk, we discovered nine new genetic risk regions. We also con-
ﬁrmed the association of genetic variants with endometrial cancer
risk at seven of the eight previously published genetic risk regions
for this disease5–8. Using this larger GWAS-meta dataset, we were
also able to conﬁrm the previously published Mendelian rando-
mization studies ﬁnding that higher BMI is causal for endometrial
cancer risk20, and the protective effect of later age of menarche on
endometrial cancer risk19. Genetic correlation analyses also
indicated a relationship between endometrial cancer and obesity-
related traits.
Candidate causal genes identiﬁed through eQTLs included
CDCA8 (1p34.3), a putative ovarian cancer oncogene24, which
encodes an essential regulator of mitosis and cell division25; RCN1
(11p13), encoding a calcium-binding protein that binds onco-
proteins such as JAK226 and MYC27; WT1-AS (11p13), a long
Table 2 Meta-analysis results for newly identiﬁed genome-wide signiﬁcant endometrial cancer risk loci
Region SNP Position
(bp)a
Nearby or candidate
gene(s)b
Effect:
other
alleles
EAF Info All histologies (12,906 cases;
108,979 controls)
Endometrioid histology
(8758 cases; 46,126
controls)
Non-endometrioid
histologies (1230 cases;
35,447 controls)
Between
histologies
Allelic
OR (95%
CI)
P I2 BFDP
(%)
Allelic
OR (95%
CI)
P I2 Allelic
OR (95%
CI)
P I2 P
1p34.3 rs113998067 37,607,755 GNL2, RSPO1, CDCA8 C:T 0.04 0.90 1.23 (1.14,
1.32)
3.6E
−08
20% 2% 1.27 (1.17,
1.38)
2.6E
−08
33% 1.21
(0.98,
1.50)
7.0E
−02
0% 0.99
2p16.1 rs148261157 60,670,444 BCL11A A:G 0.03 0.88 1.26 (1.16,
1.36)
3.4E
−08
16% 2% 1.25 (1.14,
1.38)
4.7E
−06
21% 1.64
(1.32,
2.04)
9.6E
−06
0% 0.0026
9p21.3 rs1679014 22,207,038 CDKN2A, CDKN2B T:C 0.07 G 1.18 (1.12,
1.25)
6.4E
−09
0% <1% 1.17 (1.09,
1.25)
4.4E
−06
0% 1.19 (1.02,
1.38)
3.0E
−02
6% 0.14
11p13 rs10835920 32,468,118 WT1, WT1-AS, RCN1,
CCDC73, EIF3M,
TCP11L1
T:C 0.38 0.99 1.09
(1.06,
1.13)
1.3E
−08
0% 1% 1.10 (1.05,
1.14)
2.1E
−06
0% 1.10 (1.01,
1.20)
3.8E
−02
15% 0.68
12p12.1 rs9668337 26,273,405 SSPN A:G 0.74 0.99 1.11 (1.08,
1.15)
1.1E
−09
0% <1% 1.10 (1.06,
1.15)
2.6E
−06
0% 1.10
(1.00,
1.22)
5.1E
−02
0% 0.88
12q24.11 rs3184504 111,446,804 SH2B3 C:T 0.52 G 1.10 (1.07,
1.14)
1.1E
−10
0% <1% 1.11 (1.07,
1.15)
5.8E
−09
0% 1.10 (1.01,
1.19)
3.2E
−02
4% 0.79
12q24.21 rs10850382 114,776,743 LOC107984437 T:C 0.31 G 1.10 (1.07,
1.14)
3.5E
−09
0% <1% 1.11 (1.07,
1.15)
1.5E
−07
0% 1.02
(0.93,
1.12)
6.7E
−01
0% 0.16
17q11.2 rs1129506 31,319,014 EVI2A, NF1, SUZ12,
RP11-848P1.5
G:A 0.38 G 1.10 (1.06,
1.13)
4.3E
−08
0% 4% 1.11 (1.07,
1.15)
1.3E
−07
36% 1.07
(0.98,
1.17)
1.3E
−01
13% 0.27
17q21.32 rs882380 48,216,874 SKAP1, SNX11 A:C 0.61 0.99 1.10 (1.06,
1.13)
4.7E
−09
41% <1% 1.11 (1.07,
1.15)
1.2E
−08
34% 1.08
(0.99,
1.18)
7.6E
−02
0% 0.62
EAF: effect allele frequency among control subjects in the UK Biobank, Info: imputation quality score for the OncoArray set, G: genotyped SNPs, I2: heterogeneity I2 statistic, BFDP: Bayes false discovery
probability46
aPosition is with reference to build 38 of the reference genome
bBolded genes are candidate genes identiﬁed from eQTL analysis
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non-coding RNA that regulates the WT1 oncogene28,29; SH2B3
(12p24.11) encoding a negative regulator of the oncogenic KIT
and JAK2 signal transduction proteins30; and tumor suppressor
gene NF1 (17q11.2) encoding a negative regulator of RAS-
mediated signal transduction31, which acquires putative driver
mutations in TCGA endometrial tumors (http://www.cbioportal.
org/study?id=ucec_tcga). Notably, the highly signiﬁcant eQTL
associations between ccrSNPs and expression of SH2B3 (linear
regression P ≥ 5.62 × 10−20) and NF1 (P ≥ 1.32 × 10−56) in blood
revealed risk alleles to be associated with decreased gene expres-
sion for both loci, consistent with the role of these genes in tumor
development.
Intersections of ccrSNPs with epigenomic marks mapped in
endometrial cancer cell lines, uterine tissue, and vaginal tissue
found more endometrial cancer ccrSNPs overlapped with these
features than ccrSNPs for endometriosis17 or schizophrenia18.
These ﬁndings highlight the relevance of these tissues for func-
tional studies of endometrial cancer biology. Given the estab-
lished role of estrogen in endometrial carcinogenesis32, it is
perhaps not surprising that endometrial cancer ccrSNPs exhibited
greater overlap with epigenomic features present after estrogen
stimulation. However, this ﬁnding provides evidence that
functional studies of endometrial cancer should be performed
under these conditions.
Using LD score regression, we estimated that ~28% of the
approximately twofold FRR of endometrial cancer could be
explained by variants, which can be reliably imputed from
OncoArray genotypes. The common endometrial cancer variants
identiﬁed to date together explain up to 6.8% of the FRR,
including 2.7% contributed by the nine additional variants
reported here; this may be an overestimate, given that the ORs for
the new loci likely include some upwards bias (the so-called
winner’s curse). In summary, we have doubled the number of
endometrial cancer risk loci, explaining around one quarter
(6.9%/28%) of the portion of the FRR attributable to common,
readily-imputable SNPs. Furthermore, eQTL analyses have
identiﬁed candidate causal genes and pathways related to tumor
development for follow-up studies that will provide further
insight into endometrial cancer biology.
Methods
Study samples. Analyses were based on 13 studies of endometrial cancer, of which
four studies contributed case samples to more than one genotyping project. Data
were also included from the E2C2 consortium of 45 separate studies. All
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participants were of European ancestry. Data from the E2C2 genome-wide asso-
ciation studies (GWAS) and from the ANECS, SEARCH, NSECG GWASs and the
iCOGS project have been previously published, and are described in de Vivo et al.33
and Cheng et al.6, respectively.
The OncoArray study. The “OncoArray” genotyping chip34 contains 533,631
variants, around half of which were selected to provide a “GWAS backbone,” with
the remaining variants selected on the basis of prior evidence of association with
cancer or a cancer-related trait. The OncoArray chip was used to genotype 5061
endometrial cancer cases from ten studies in Australia, Belgium, Germany, Sweden,
UK, and USA. Genotyping was carried out at two sites: the Center for Inherited
Disease Research (CIDR; nine studies) and The University of Melbourne (one
study). Details of the genotype calling are given in Amos et al.34
SNP-wise QC was conducted using genotype data from all consortia
participating in the OncoArray experiment34. SNPs with call rate <95% in any of
the consortia, SNPs not in Hardy–Weinberg equilibrium (HWE) (P < 10−7 in
controls and P < 10−12 in cases) and SNPs with concordance <98% among 5280
duplicate pairs of samples were excluded, leaving 483,972 SNPs. Prior to
imputation, SNPs with minor allele frequency (MAF) <1% and call rate <98% in
any consortium were also excluded, as were SNPs that could not be linked to the
1000 Genomes Project reference panel or for which the MAF differed signiﬁcantly
from the European reference panel frequency. A further 1128 SNPs were excluded
after review of cluster plots, hence 469,364 SNPs were used in the imputation.
The 5061 OncoArray-genotyped endometrial cancer cases were country-
matched to controls who had been genotyped in an identical process as part of the
Breast Cancer Association Consortium35,36. Samples with call rate <95%, with
excessively low or high heterozygosity or with an estimated proportion of European
ancestry <80% (based on a principal components analysis of 2318 informative
markers and with reference to the HapMap populations) were excluded, as were
suspected males and individuals who were XO or XXY.
Duplicates and close relatives were identiﬁed from estimated genomic kinship
matrices. Pairwise comparisons were made among all samples genotyped as part of
the OncoArray, iCOGS, or ANECS/SEARCH/NSECG GWAS genotyping projects.
Where pairs of duplicates or close relatives were identiﬁed between projects, the
sample with the more recent genotyping was retained, hence the numbers of cases
included here from the ANECS/SEARCH/NSECG GWASs and iCOGS projects are
lower than in the original publications. For case–control pairs from within the
same project, the case was preferentially retained, and for case–case or
control–control pairs, the sample with the higher call rate was used. Following
these exclusions, OncoArray genotypes from 4710 cases and 19,438 controls were
included in the analyses.
All OncoArray samples (along with all samples from the ANECS/SEARCH/
NSECG GWASs and the iCOGS project) were imputed using the October 2014
(version 3) release of the 1000 Genomes Project reference panel. Samples were
phased using SHAPEITv237 and genotypes were imputed using the IMPUTEv238
software for non-overlapping 5-Mb intervals. Analyses were restricted to the ~11.4
million SNPs with MAF >0.5% and r2 > 0.4.
Other studies. The 2695 cases and 2777 controls from the E2C2 consortium were
genotyped using the Illumina Human OmniExpress array (2271 cases, 2219 con-
trols from the United States) or the Illumina Human 660W array (424 cases, 558
controls from Poland)33 and both sets were separately imputed to the 1000 Gen-
omes Project v3 reference panel using “minimac2” software, following standard
quality control steps38,39.
The 288 cases from six population-based case–control studies within the
Women’s Health Initiative were genotyped using ﬁve different arrays
(Supplementary Data 1) and were each separately imputed using the combined
1000 Genome Project v3 and UK10K reference panels using “minimac2”
software39, following standard quality measures and the exclusion of SNPs with a
MAF <1%. Five controls for each case were selected randomly, matched on study.
Data were also included from the ﬁrst phase of UK Biobank genotyping,
comprising 636 Cancer Registry-conﬁrmed endometrial cancer cases (as of October
2016) and 62,853 cancer-free female controls. Samples were genotyped using
Affymetrix UK BiLEVE Axiom array and Affymetrix UK Biobank Axiom® array
and imputed to the combined 1000 Genome Project v3 and UK10K reference
panels using SHAPEIT340 and IMPUTE341.
No analyses to identify duplicates or relatives between samples from the E2C2,
WHI, or UK Biobank studies, and any other study were carried out. However,
given the sampling frame of these studies, it is very unlikely that there would have
been any meaningful sample overlap.
After QC exclusions, the analysis included 12,906 endometrial cancer cases
(3613 of which have not been included in any previous publication) and 108,979
controls. Analyses were also carried out speciﬁcally for endometrial cancer
of endometrioid histology (8758 cases) and endometrial cancer with non-
endometrioid histology (1230 cases). Exploratory analyses for speciﬁc non-
endometrioid histologies (serous carcinoma, carcinosarcoma, clear cell carcinoma,
and mucinous carcinoma) included a small number of cases of mixed histotype,
where the major component was non-endometrioid. The UK Biobank data did not
include information about histology.
All participating studies were approved by research ethics committees from
QIMR Berghofer Medical Research Institute, University-Clinic Erlangen,
Karolinska Institutet, UZ Leuven, The Mayo Clinic, The Hunter New England
Health District, The Regional Committees for Medical and Health Research Ethics
Norway, and the UK National Research Ethics Service (04/Q0803/148 and 05/
MRE05/1). All participants provided written, informed consent.
Statistical analyses. Per-allele ORs and the s.e. of the logORs were computed
using logistic regression for each of the ANECS, SEARCH, NSECG, WHI, and UK
Biobank GWASs, for the two E2C2 GWASs and, by country, for the iCOGS and
OncoArray studies, giving a total of 17 strata. Case-only analyses were used to
assess heterogeneity in SNP effects by histology (endometrioid histology versus
non-endometrioid histology). In the OncoArray analysis, potential population
stratiﬁcation was adjusted for using the ﬁrst nine principal components; these were
estimated using data for 33,661 uncorrelated SNPs with MAF >0.05 and pairwise
r2 < 0.1 (including 2318 SNPs speciﬁcally selected as informative for continental
ancestry) using purpose-written software (http://ccge.medschl.cam.ac.uk/software/
pccalc). Other studies were similarly adjusted for their relevant principal
components.
Analyses were carried out using SNPTEST42 for the ANECS, SEARCH, and
NSECG GWASs, using ProbABEL43 for the E2C2 GWASs, and using in house
software for the iCOGS, OncoArray, WHI, and UK Biobank studies. We assessed
residual population stratiﬁcation by computing the test statistic inﬂation
Table 3 Effects of genetically predicted anthropometric and reproductive traits on risk of endometrial cancer
Trait Instrumental variable SNPs Endometrial cancer Endometrial cancer Endometrial cancer
All histology (OR
and 95% CI)
Endometrioid histology (OR
and 95% CI)
Non-endometrioid histology
(OR and 95% CI)
Body mass index (BMI)a 77 SNPs49 1.92 (1.63, 2.25),
P= 1.7E−11
2.04 (1.69, 2.46), P= 8.6E −11 1.65 (1.13, 2.41), P= 0.011
Waist:hip ratio 47 SNPs50 0.95 (0.72, 1.25),
P= 0.71
0.94 (0.71, 1.24), P= 0.66 1.27 (0.69, 2.33), P= 0.45
Age at menarche (years);
total effect
368 SNPs19 0.82 (0.77, 0.87),
P= 2.2E−9
0.80 (0.74, 0.86), P= 1.9E−9 0.93 (0.79, 1.08), P= 0.33
Age at menarche (years);
direct effectb
368 SNPs19, BMI weights
from Locke et al.49
0.88 (0.82, 0.94),
P= 3.8E−4
0.86 (0.79, 0.93), P= 2.7E−4 0.97 (0.82, 1.16), P= 0.76
Age at natural
menopause (years)
54 SNPs53 1.03 (1.00, 1.06),
P= 0.060
1.02 (0.99, 1.06), P= 0.19 1.07 (0.99, 1.14), P= 0.075
Adult height 814 SNPs51, 52 1.00 (0.95, 1.06),
P= 0.90
0.99 (0.93, 1.05), P= 0.63 1.00 (0.88, 1.15), P= 0.95
Odds ratios (ORs) are per year for age at menarche and for age at natural menopause, but are not in meaningful units for the other traits because the published SNP-trait associations are in terms of
inverse-rank normalized residuals
aNote, none of the endometrial cancer risk variants identiﬁed to date have been directly related to BMI-associated SNPs, or BMI monogenic disorders
bThe direct effect of age at menarche on endometrial cancer risk is adjusted for the mediating effect of genetically predicted BMI54
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adjusted to a sample size of 1000 cases and 1000 controls (λ1000’s), both overall
and with each strata, using 33,278 uncorrelated SNPs (r2 < 0.1). The overall λ1000
was 1.004, with stratum-speciﬁc λ1000’s between 0.996 and 1.128 (observed for
the smallest strata, the German iCOGS dataset; Supplementary ﬁg. 1).
The estimated ORs from the different studies were combined in a ﬁxed-effects
inverse-variance weighted meta-analysis using the “meta” software44. For each
variant, results from any strata for which the imputation information score was
<0.4, the MAF <0.005 or the OR >3 or <0.333 were excluded. Following the meta-
analysis, SNPs with valid results in fewer than two of the strata, or with between-
strata heterogeneity P < 5 × 10−8 were also excluded, leaving 11.7 million SNPs. A
random-effects meta-analysis was also carried out.
Using the conventional 5 × 10−8 genome-wide signiﬁcance threshold, all SNPs
lying within ± 500 kb of a signiﬁcant SNP were initially considered as part of that
locus. Approximate conditional analysis in the GCTA program11,45 with an LD
reference panel of 4000 OncoArray-genotyped control subjects were then used to
look for additional independently associated SNPs within each locus. Only
uncorrelated (r2 < 0.05) secondary signals were included. The only locus with
evidence of signiﬁcant signals after conditioning on the most strongly associated
SNP was the previously published 8q24 locus6 (Table 1). For each locus, the set of
credible causal risk SNPs (ccrSNPs) was deﬁned as those variants within ± 500 kb
of the most signiﬁcant SNP and for which the likelihood from the association
analysis was no less than one hundredth the likelihood of the most signiﬁcant SNP
(i.e., odds of <1 : 100). A BFDP for each signiﬁcant SNP was estimated on the basis
of a maximum plausible OR of 1.5 and a prior probability of association of
0.000146.
The proportion of the FRR of endometrial cancer due to the identiﬁed variants
was estimated using a log-additive model, where pj, βj, and τj are the MAF, logOR,
and se(logOR), respectively for variant j, and λ= 2 is the reported FRR of
endometrial cancer. The effect estimates used were those estimated in the current
study, both for the new loci and for the loci replicated from previous studies.
Proportion FRR ¼ 1
ln λð Þ
X
j
pjð1 pjÞðβ2j  τ2j Þ:
The proportion of the endometrial cancer FRR that can be explained by all SNPs
is given by the frailty-scale heritability, hf2, divided by 2ln(λ). This was estimated
using LD score regression47, based on the full set of meta-analysis summary
estimates, restricted to those SNPs present on the HapMap v3 dataset with MAF
>1% and imputation quality R2 > 0.9 in the OncoArray imputation using the
1000 Genomes Phase 3 reference panel. The frailty-scale heritability (as opposed
to the observed-scale heritability) was obtained by replacing the total sample, N,
for each study with an effective sample size Nj for SNP j, which effectively
weights each SNP according to its frequency and the variance of the effect
estimate, i.e.,
Nj¼
1
2pj 1 pj
 
τ2j
:
Cross-trait LD score regression via the LD Hub interface (28 September 2017,
v1.4.1) was used to estimate the genetic correlations between endometrial cancer
and 224 traits from 24 categories23.
The casual effects of ﬁve anthropometric or reproductive factors on the risks of
endometrial cancer were estimated using two-sample summary statistic inverse-
variance weighted MR analyses48. Instrumental variables for each factor consisted
of the most recent set of published GWAS-signiﬁcant SNPs for that trait; 77 SNPs
for body mass index (BMI)49, 47 SNPs for waist:hip ratio50, 814 SNPs for adult
height51,52, 54 SNPs for age at natural menopause53, and 368 SNPs for age at
menarche19. A multivariable MR adjusting for the effects of the 368 menarche
SNPs on BMI (a potential mediator) was used to estimate the direct effect of
menarche on endometrial cancer, not via BMI54.
Cell culture. Ishikawa and JHUEM-14 cells were a gift from Prof PM Pollock
(Queensland University of Technology). Cell lines were authenticated using STR
proﬁling and conﬁrmed to be negative for mycoplasma contamination. Ishikawa
cells were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Life
Technologies #1195-065) with 10% fetal bovine serum (FBS) and antibiotics
(100 IU/ml penicillin and 100 μg/ml streptomycin). JHUEM-14 cells were cul-
tured in DMEM/F12 medium (Life Technologies #11320-033) with 10% FBS and
antibiotics.
Cell ﬁxing and chromatin shearing. Ishikawa and JHUEM-14 cells were plated
on to 10-cm tissue culture dishes in phenol red-free DMEM (Sigma-Aldrich
#D1145) supplemented with L-glutamine, sodium pyruvate, and 10% charcoal-
dextran-stripped FBS. Three days later, media were replaced and cells incubated
with fresh medium containing either 10 nM estradiol or DMSO (vehicle control)
for 3 h. Cells were washed twice with PBS and ﬁxed at room temperature in 1%
formaldehyde in PBS. After 10 min, cells were placed on ice and washed twice
with ice-cold PBS. The reaction was quenched with 10 mM DTT in 100 mM
Tris-HCl (pH 9.4) and cells removed from the dish with a cell scraper. Cells were
incubated at 30 °C for 15 min, then spun for 5 min at 2000×g. Cells were washed
sequentially with ice-cold PBS, buffer I (0.25% Triton X-100, 10 mM EDTA,
0.5 mM EGTA, 10 mM HEPES, pH 6.5) and buffer II (200 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 10 mM HEPES, pH 6.5) and centrifuged for 5 min at
2000×g at 4 °C. Cells were resuspended in 300–750 μl of lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris-HCl, pH 8.1, with complete protease inhibitor
cocktail (Sigma-Aldrich #11836145001)). Ishikawa cells were sonicated for eight
cycles (10 s) and JHUEM-14 cells for 20 cycles using the highest power setting of
a Branson Digital Soniﬁer SLPt. After chromatin shearing was conﬁrmed by
agarose gel electrophoresis, samples were centrifuged for 10 min at 4 °C.
Chromatin immunoprecipitation and sequencing. Samples were diluted 10-fold
in 1% Triton X-100, 2 mM EDTA, 20 mM Tris.HCl (pH 8.1), and 150 mM NaCl
with complete protease inhibitor cocktail. Magna ChIP protein A/G magnetic
beads (EMD Millipore #16-663) were added to 500 μl of diluted chromatin and
incubated with 5 μg of antibody overnight at 4 °C. Antibodies to H3K4Me1
(Abcam #ab8895), H3K4Me3 (Abcam #ab8580), and H3K27Ac (Abcam
#ab4729) were used (Supplementary Table 1). The next day supernatant was
removed and the beads washed three times with the following ice-cold buffers:
RIPA 150 (0.1% SDS, 1% Triton X-100, 1 mM EDTA, 50 mM Tris-HCl (pH 8.10,
150 mM NaC1, 0.1% sodium deoxycholate), RIPA 500 (0.1% SDS, 1% Triton X-
100, 1 mM EDTA, 50 mM Tris-HCl (pH 8.10, 500 mM NaC1, 0.1% sodium
deoxycholate), LiCl RIPA (500 mM LiCl, 1% NP-40, 1% deoxycholate, 1 mM
EDTA, 50 mM Tris-HCl (pH 8.1)), and TE buffer. Chromatin was then eluted
by incubating beads overnight at 60 °C with 100 μl of elution buffer (1% SDS,
100 mM NaHCO3) and 0.5 mg/ml proteinase K. The next day beads were
incubated at 95 °C for 10 min and supernatant removed. Chromatin was puriﬁed
using the QIAquick Spin kit (QIAGEN) and eluted from columns using 50 μl of
QIAGEN EB buffer. DNA was quantiﬁed using a Qubit dsDNA HS Assay kit
(ThermoFisher Scientiﬁc).
Samples from two biological replicates for each treatment were sent to the
Australian Genome Research Facility (Melbourne, Australia) for library
preparation and sequencing (Illumina HiSeq 2500) with 50 bp reads. Mapping and
analysis of ChIP-seq reads were performed using the ENCODE analysis pipeline,
histone ChIP-seq Unary Control (GRCh37), with DNAnexus software tools
(https://dnanexus.com). Replicated peaks across biological replicates were used for
downstream analyses.
eQTL analyses. Summary eQTL results for non-cancer tissue were obtained
using uterine (N= 70) and vaginal (N= 79) tissue-speciﬁc data generated by
the Genotype-Tissue Expression Project (GTEx)12, an endometrium eQTL dataset
(N= 123) provided by Fung et al.14, and a blood eQTL dataset (males and females;
N= 5311)15.
Data from endometrial cancer tumors and adjacent normal endometrial
tissue were accessed from The Cancer Genome Atlas13. Patient germ line SNP
genotypes (Affymetrix 6.0 arrays) and tissue expression RNA-seq data were
downloaded through the controlled access portal, while epidemiological and
tumor tissue copy-number data were downloaded through the public access
portal. RNA-seq data were aligned and expression quantiﬁed to reads per
kilobase per million (RPKM) as described in Painter et al.10 and quality control
performed on the germ line SNP genotypes as per Carvajal-Carmona et al.55
Complete genotype, RNA-seq, and copy-number data were available for 277
genetically European patients (218 with endometrioid histology, 29 with
adjacent normal tissue).
Germ line genotypes underwent further quality control before imputation to the
1000 Genomes Phase 3v5 reference panel by Eagle v2.356, using the Michigan
Imputation Server57. Brieﬂy, subjects were removed for genotype missingness
>10% and SNPs were removed for missingness >10%, MAF <5%, and HWE P-
value <5 × 10−8. SNPs were also removed if they were indels or non-biallelic
variants, were ambiguous SNPs with a MAF >40%, were not matched to the
reference panel, had a MAF difference with the reference panel of >20%, or were
duplicates.
Genes with a median expression level of 0 RPKM across samples were removed,
and the RPKM values of each gene were log2-transformed and samples were
quantile normalized. The expression of the genes located within a 2-Mb window
surrounding the ccrSNP at each of the newly identiﬁed risk loci were extracted
from the expression dataset.
The associations between ccrSNPs and gene expression in all endometrial
cancer tumor tissues, endometrioid endometrial cancer tissues only, and
adjacent normal endometrial tissue, were evaluated using linear regression
models using the MatrixEQTL program in R58, adjusting for sequencing
platform. Tumor tissue expression was also adjusted for copy-number variation,
as previously described in Li et al.59 A false discovery rate of <20% was used to
report eQTL results from all datasets, except for the endometrium eQTL dataset
where we used a P-value <0.01.
Candidate causal gene network analysis. Candidate causal genes identiﬁed
in our previous studies and from the eQTL results in the current study (Sup-
plementary Table 6) were analyzed using Ingenuity Pathway Analysis (QIAGEN;
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accessed on 23 March 2018 and available at www.qiagen.com/ingenuity) to
deﬁne gene networks and enrichment of genes in canonical signaling pathways.
Data availability. OncoArray germ line genotype data for the ECAC studies and
E2C2 germ line genotype data have been deposited through the database of
Genotypes and Phenotypes (dbGaP; accession number phs000893.v1.p1). Meta-
GWAS summary statistics are available from the authors by request. Genotype data
for non-cancer controls were provided by the Breast Cancer Association Con-
sortium (BCAC) by application to the BCAC Data Access Coordination Com-
mittee (http://bcac.ccge.medschl.cam.ac.uk/). ChIP-seq data are available from the
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under
accession number GSE113818.
Received: 25 December 2017 Accepted: 2 July 2018
References
1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods
and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386
(2015).
2. Win, A. K., Reece, J. C. & Ryan, S. Family history and risk of endometrial
cancer: a systematic review and meta-analysis. Obstet. Gynecol. 125, 89–98
(2015).
3. Johnatty, S. E. et al. Family history of cancer predicts endometrial cancer risk
independently of Lynch syndrome: implications for genetic counselling.
Gynecol. Oncol. 147, 381–387 (2017).
4. Spurdle, A. B., Bowman, M. A., Shamsani, J. & Kirk, J. Endometrial cancer
gene panels: clinical diagnostic vs research germline DNA testing. Mod.
Pathol. 30, 1048–1068 (2017).
5. Chen, M. M. et al. GWAS meta-analysis of 16852 women identiﬁes new
susceptibility locus for endometrial cancer. Hum. Mol. Genet. 25, 2612–2620
(2016).
6. Cheng, T. H. et al. Five endometrial cancer risk loci identiﬁed through
genome-wide association analysis. Nat. Genet. 48, 667–674 (2016).
7. Painter, J. N. et al. Fine-mapping of the HNF1B multicancer locus identiﬁes
candidate variants that mediate endometrial cancer risk. Hum. Mol. Genet. 24,
1478–1492 (2015).
8. Thompson, D. J. et al. CYP19A1 ﬁne-mapping and Mendelian randomization:
estradiol is causal for endometrial cancer. Endocr. Relat. Cancer 23, 77–91
(2016).
9. Cheng, T. H. et al. Meta-analysis of genome-wide association studies identiﬁes
common susceptibility polymorphisms for colorectal and endometrial cancer
near SH2B3 and TSHZ1. Sci. Rep. 5, 17369 (2015).
10. Painter, J. N. et al. A common variant at the 14q32 endometrial cancer risk
locus activates AKT1 through YY1 binding. Am. J. Hum. Genet. 98,
1159–1169 (2016).
11. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool
for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82
(2011).
12. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat.
Genet. 45, 580–585 (2013).
13. Cancer Genome Atlas Research Network et al. Integrated genomic
characterization of endometrial carcinoma. Nature 497, 67–73 (2013).
14. Fung, J. N. et al. The genetic regulation of transcription in human endometrial
tissue. Hum. Reprod. 32, 893–904 (2017).
15. Westra, H. J. et al. Systematic identiﬁcation of trans eQTLs as putative drivers
of known disease associations. Nat. Genet. 45, 1238–1243 (2013).
16. ENCODE Project Consortium. An integrated encyclopedia of DNA elements
in the human genome. Nature 489, 57–74 (2012).
17. Sapkota, Y. et al. Meta-analysis identiﬁes ﬁve novel loci associated with
endometriosis highlighting key genes involved in hormone metabolism. Nat.
Commun. 8, 15539 (2017).
18. Schizophrenia Working Group of the Psychiatric Genomics Consortium.
Biological insights from 108 schizophrenia-associated genetic loci. Nature 511,
421–427 (2014).
19. Day, F. R. et al. Genomic analyses identify hundreds of variants associated
with age at menarche and support a role for puberty timing in cancer risk.
Nat. Genet. 49, 834–841 (2017).
20. Painter, J. N. et al. Genetic risk score mendelian randomization shows that
obesity measured as body mass index, but not waist:hip ratio, is causal for
endometrial cancer. Cancer Epidemiol. Biomarkers Prev. 25, 1503–1510
(2016).
21. Zhang, B. et al. Height and breast cancer risk: evidence from prospective
studies and Mendelian randomization. J. Natl Cancer Inst. 107, djv219 (2015).
22. Khankari, N. K. et al. Association between adult height and risk of colorectal,
lung, and prostate cancer: results from meta-analyses of prospective studies
and mendelian randomization analyses. PLoS Med. 13, e1002118 (2016).
23. Zheng, J. et al. LD Hub: a centralized database and web interface to perform
LD score regression that maximizes the potential of summary level GWAS
data for SNP heritability and genetic correlation analysis. Bioinformatics 33,
272–279 (2017).
24. Wrzeszczynski, K. O. et al. Identiﬁcation of tumor suppressors and oncogenes
from genomic and epigenetic features in ovarian cancer. PLoS ONE 6, e28503
(2011).
25. Ruchaud, S., Carmena, M. & Earnshaw, W. C. Chromosomal passengers:
conducting cell division. Nat. Rev. Mol. Cell Biol. 8, 798–812 (2007).
26. So, J. et al. Integrative analysis of kinase networks in TRAIL-induced apoptosis
provides a source of potential targets for combination therapy. Sci. Signal. 8,
rs3 (2015).
27. Agrawal, P., Yu, K., Salomon, A. R. & Sedivy, J. M. Proteomic proﬁling of
Myc-associated proteins. Cell Cycle 9, 4908–4921 (2010).
28. McCarty, G. & Loeb, D. M. Hypoxia-sensitive epigenetic regulation of an
antisense-oriented lncRNA controls WT1 expression in myeloid leukemia
cells. PLoS ONE 10, e0119837 (2015).
29. Moorwood, K. et al. Antisense WT1 transcription parallels sense mRNA and
protein expression in fetal kidney and can elevate protein levels in vitro. J.
Pathol. 185, 352–359 (1998).
30. Devalliere, J. & Charreau, B. The adaptor Lnk (SH2B3): an emerging regulator
in vascular cells and a link between immune and inﬂammatory signaling.
Biochem. Pharmacol. 82, 1391–1402 (2011).
31. Rad, E. & Tee, A. R. Neuroﬁbromatosis type 1: fundamental insights into cell
signalling and cancer. Semin. Cell Dev. Biol. 52, 39–46 (2016).
32. Setiawan, V. W. et al. Type I and II endometrial cancers: have they different
risk factors? J. Clin. Oncol. 31, 2607–2618 (2013).
33. De Vivo, I. et al. Genome-wide association study of endometrial cancer in
E2C2. Hum. Genet. 133, 211–224 (2014).
34. Amos, C. I. et al. The OncoArray Consortium: a network for understanding
the genetic architecture of common cancers. Cancer Epidemiol. Biomarkers
Prev. 26, 126–135 (2017).
35. Michailidou, K. et al. Association analysis identiﬁes 65 new breast cancer risk
loci. Nature 551, 92–94 (2017).
36. Milne, R. L. et al. Identiﬁcation of ten variants associated with risk of estrogen-
receptor-negative breast cancer. Nat. Genet. 49, 1767–1778 (2017).
37. Delaneau, O., Marchini, J., 1000 Genomes Project Consortium & 1000
Genomes Project Consortium. Integrating sequence and array data to create
an improved 1000 Genomes Project haplotype reference panel. Nat. Commun.
5, 3934 (2014).
38. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast
and accurate genotype imputation in genome-wide association studies
through pre-phasing. Nat. Genet. 44, 955–959 (2012).
39. Fuchsberger, C., Abecasis, G. R. & Hinds, D. A. minimac2: faster genotype
imputation. Bioinformatics 31, 782–784 (2015).
40. O’Connell, J. et al. Haplotype estimation for biobank-scale data sets. Nat.
Genet. 48, 817–820 (2016).
41. Bycroft, C. et al. Genome-wide genetic data on ~500,000 UK Biobank
participants. Preprint at https://www.biorxiv.org/content/early/2017/07/20/
166298 (2017).
42. Marchini, J. & Howie, B. Genotype imputation for genome-wide association
studies. Nat. Rev. Genet. 11, 499–511 (2010).
43. Aulchenko, Y. S., Struchalin, M. V. & van Duijn, C. M. ProbABEL package for
genome-wide association analysis of imputed data. BMC Bioinformatics 11,
134 (2010).
44. Liu, J. Z. et al. Meta-analysis and imputation reﬁnes the association of 15q25
with smoking quantity. Nat. Genet. 42, 436–440 (2010).
45. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary
statistics identiﬁes additional variants inﬂuencing complex traits. Nat. Genet.
44, 369–375 (2012).
46. Wakeﬁeld, J. A Bayesian measure of the probability of false discovery in
genetic epidemiology studies. Am. J. Hum. Genet. 81, 208–227 (2007).
47. Bulik-Sullivan, B. K. et al. LD score regression distinguishes confounding from
polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295
(2015).
48. Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on
multiple instrumental variables in Mendelian randomization: comparison of
allele score and summarized data methods. Stat. Med. 35, 1880–1906 (2016).
49. Locke, A. E. et al. Genetic studies of body mass index yield new insights for
obesity biology. Nature 518, 197–206 (2015).
50. Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat
distribution. Nature 518, 187–196 (2015).
51. Wood, A. R. et al. Deﬁning the role of common variation in the genomic and
biological architecture of adult human height. Nat. Genet. 46, 1173–1186
(2014).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05427-7
8 NATURE COMMUNICATIONS |  (2018) 9:3166 | DOI: 10.1038/s41467-018-05427-7 | www.nature.com/naturecommunications
52. Marouli, E. et al. Rare and low-frequency coding variants alter human adult
height. Nature 542, 186–190 (2017).
53. Day, F. R. et al. Large-scale genomic analyses link reproductive aging to
hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated
DNA repair. Nat. Genet. 47, 1294–1303 (2015).
54. Burgess, S. et al. Dissecting causal pathways using Mendelian randomization
with summarized genetic data: application to age at menarche and risk of
breast cancer. Genetics 207, 481–487 (2017).
55. Carvajal-Carmona, L. G. et al. Candidate locus analysis of the TERT-
CLPTM1L cancer risk region on chromosome 5p15 identiﬁes multiple
independent variants associated with endometrial cancer risk. Hum. Genet.
134, 231–245 (2015).
56. Loh, P. R. et al. Reference-based phasing using the Haplotype Reference
Consortium panel. Nat. Genet. 48, 1443–1448 (2016).
57. Das, S. et al. Next-generation genotype imputation service and methods. Nat.
Genet. 48, 1284–1287 (2016).
58. Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix
operations. Bioinformatics 28, 1353–1358 (2012).
59. Li, Q. et al. Integrative eQTL-based analyses reveal the biology of breast cancer
risk loci. Cell 152, 633–641 (2013).
Acknowledgements
We thank the many individuals who participated in this study and the numerous
institutions and their staff who supported recruitment, detailed in full in the Sup-
plementary Information. The iCOGS and OncoArray endometrial cancer analysis
were supported by NHMRC project grants (ID#1031333 and ID#1109286) to A.B.S.,
D.F.E., A.M.D., D.J.T., and I.T. A.B.S. (APP1061779), P.M.W., and T.A.O’.
M. (APP1111246) are supported by the NHMRC Fellowship scheme. A.M.D. was
supported by the Joseph Mitchell Trust. I.T. is supported by Cancer Research UK and
the Oxford Comprehensive Biomedical Research Center. Funding for the iCOGS
infrastructure came from: the European Community's Seventh Framework Pro-
gramme under grant agreement no. 223175 (HEALTH-F2-2009-223175) (COGS),
Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/
A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National
Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537,
1U19 CA148065 and 1U19 CA148112—the GAME-ON initiative), the Department of
Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR)
for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the
Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.
OncoArray genotyping of ECAC cases was performed with the generous assistance of
the Ovarian Cancer Association Consortium (OCAC). We particularly thank the
efforts of Cathy Phelan. The OCAC OncoArray genotyping project was funded
through grants from the US National Institutes of Health (CA1X01HG007491-01
(Christopher I. Amos), U19-CA148112 (Thomas A. Sellers), R01-CA149429 (Cathe-
rine M. Phelan), and R01-CA058598 (Marc T. Goodman)); Canadian Institutes of
Health Research (MOP-86727 (Linda E. Kelemen)); and the Ovarian Cancer Research
Fund (Andrew Berchuck). CIDR genotyping for the Oncoarray was conducted under
contract 268201200008I. OncoArray genotyping of the BCAC controls was funded by
Genome Canada Grant GPH-129344, NIH Grant U19 CA148065, and Cancer UK
Grant C1287/A16563.
ANECS recruitment was supported by project grants from the NHMRC (ID#339435),
The Cancer Council Queensland (ID#4196615), and Cancer Council Tasmania
(ID#403031 and ID#457636). SEARCH recruitment was funded by a programme grant
from Cancer Research UK (C490/A10124). Stage 1 and stage 2 case genotyping was
supported by the NHMRC (ID#552402, ID#1031333). Control data were generated by
the Wellcome Trust Case Control Consortium (WTCCC), and a full list of the
investigators who contributed to the generation of the data is available from the
WTCCC website. We acknowledge use of DNA from the British 1958 Birth Cohort
collection, funded by the Medical Research Council grant G0000934 and the Well-
come Trust grant 068545/Z/02—funding for this project was provided by the Well-
come Trust under award 085475. NSECG was supported by the EU FP7 CHIBCHA
grant, Wellcome Trust Centre for Human Genetics Core Grant 090532/Z/09Z, and
CORGI was funded by Cancer Research UK. We thank Nick Martin, Dale Nyholt, and
Anjali Henders for access to GWAS data from QIMR Controls. Recruitment of the
QIMR controls was supported by the NHMRC. The University of Newcastle, the
Gladys M Brawn Senior Research Fellowship scheme, The Vincent Fairfax Family
Foundation, the Hunter Medical Research Institute, and the Hunter Area Pathology
Service all contributed toward the costs of establishing the Hunter Community Study.
The Bavarian Endometrial Cancer Study (BECS) was partly funded by the ELAN fund of
the University of Erlangen. The Hannover-Jena Endometrial Cancer Study was partly
supported by the Rudolf Bartling Foundation. The Leuven Endometrium Study (LES)
was supported by the Verelst Foundation for endometrial cancer. The Mayo Endometrial
Cancer Study (MECS) and Mayo controls (MAY) were supported by grants from the
National Cancer Institute of United States Public Health Service (R01 CA122443, P30
CA15083, P50 CA136393, and GAME-ON the NCI Cancer Post-GWAS Initiative U19
CA148112), the Fred C and Katherine B Andersen Foundation, the Mayo Foundation,
and the Ovarian Cancer Research Fund with support of the Smith family, in memory of
Kathryn Sladek Smith. MoMaTEC received ﬁnancial support from a Helse Vest Grant,
the University of Bergen, Melzer Foundation, The Norwegian Cancer Society (Harald
Andersens legat), The Research Council of Norway and Haukeland University Hospital.
The Newcastle Endometrial Cancer Study (NECS) acknowledges contributions from the
University of Newcastle, The NBN Children’s Cancer Research Group, Ms. Jennie
Thomas, and the Hunter Medical Research Institute. RENDOCAS was supported
through the regional agreement on medical training and clinical research (ALF) between
Stockholm County Council and Karolinska Institutet (numbers: 20110222, 20110483,
20110141 and DF07015), The Swedish Labor Market Insurance (number 100069), and
The Swedish Cancer Society (number 11 0439). The Cancer Hormone Replacement
Epidemiology in Sweden Study (CAHRES, formerly called The Singapore and Swedish
Breast/Endometrial Cancer Study; SASBAC) was supported by funding from the Agency
for Science, Technology and Research of Singapore (A*STAR), the US National Institutes
of Health, and the Susan G. Komen Breast Cancer Foundation. The WHI program is
funded by the National Heart, Lung, and Blood Institute, the US National Institutes of
Health, and the US Department of Health and Human Services (HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, and HHSN271201100004C). This work was also funded by NCI
U19 CA148065-01.
The Nurses’ Health Study (NHS) is supported by the NCI, NIH Grants Number UM1
CA186107, P01 CA087969, R01 CA49449, 1R01 CA134958, and 2R01 CA082838. We
thank the participants and staff of the Nurses’ Health Study for their valuable con-
tributions as well as the following state cancer registries for their help: AL, AZ, AR,
CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY,
NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. We assume full
responsibility for analyses and interpretation of these data. We also thank Channing
Division of Network Medicine, Department of Medicine, Brigham and Women’s
Hospital, and Harvard Medical School. Finally, we also acknowledge Pati Soule and
Hardeep Ranu for their laboratory assistance. The Connecticut Endometrial Cancer
Study was supported by NCI, NIH Grant Number RO1CA98346. The Fred Hutch-
inson Cancer Research Center (FHCRC) is supported by NCI, NIH Grant Number
NIH RO1 CA105212, RO1 CA 87538, RO1 CA75977, RO3 CA80636, NO1 HD23166,
R35 CA39779, KO5 CA92002, and funds from the Fred Hutchinson Cancer Research
Center. The Multiethnic Cohort Study (MEC) is supported by the NCI, NHI Grants
Number CA54281, CA128008, and 2R01 CA082838. The California Teachers Study
(CTS) is supported by NCI, NIH Grant Number 2R01 CA082838, R01 CA91019, and
R01 CA77398, and contract 97-10500 from the California Breast Cancer Research
Fund. The Polish Endometrial Cancer Study (PECS) is supported by the Intramural
Research Program of the NCI. The Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial (PLCO) is supported by the Extramural and the Intramural Research
Programs of the NCI.
The WHI program is funded by the National Heart, Lung, and Blood Institute, National
Institutes of Health, U.S. Department of Health and Human Services through contracts,
HHSN268201600018C, HHSN268201600001C, HHSN268201600002C,
HHSN268201600003C, and HHSN268201600004C. This manuscript was prepared in
collaboration with investigators of the WHI, and has been reviewed and/or approved by
the Women’s Health Initiative (WHI). WHI investigators are listed at https://www.whi.
org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%
20Short%20List.pdf.
The Breast Cancer Association Consortium (BCAC) is funded by Cancer Research UK
(C1287/A10118, C1287/A12014). The Ovarian Cancer Association Consortium (OCAC)
is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by
the family and friends of Kathryn Sladek Smith (PPD/RPCI.07), and the UK National
Institute for Health Research Biomedical Research Centres at the University of Cam-
bridge. This research has been conducted using the UK Biobank Resource under
applications 5122 and 9797. We gratefully acknowledge the TCGA endometrial cancer
consortium for providing samples, tissues, data processing, and making data and results
available. Additional funding for individual control groups is detailed in the Supple-
mentary Information.
Author contributions
T.A.O’M., D.J.T., A.B.S., and D.F.E. designed the study; T.A.O’M., D.J.T., D.M.G., and A.
B.S. drafted the manuscript; T.A.O’M. and D.J.T. conducted statistical analyses and
genotype imputation; T.A.O’M. and D.M.G. conducted bioinformatic analyses; T.A.
O’M., J.F., and G.W.M. conducted eQTL analyses; D.M.G. and T.A.O’M. performed and
analyzed ChIP-seq experiments; T.A.O’M. co-ordinated the iCOGS and OncoArray case
genotyping, and associated data management; J.D., J.P.T., and K.M. co-ordinated quality
control and data cleaning for the iCOGS and OncoArray control datasets; A.B.S. and T.
A.O’M. co-ordinated the ANECS stage 1 genotyping; A.M.D. and C.S.H. co-ordinated
the SEARCH stage 1 genotyping; I.T. and CHIBCHA funded and implemented the
NSECG GWAS; I.T., L.M., M.G., A.J., and S.H. co-ordinated the National Study of
Endometrial Cancer Genetics (NSECG), and collation of CORGI control GWAS data; A.
B.S. and P.M.W. co-ordinated the Australian National Endometrial Cancer Study
(ANECS); R.J.S., M.M.C.E., J.A., and E.G.H. co-ordinated collation of GWAS data for the
Hunter Community Study; P.D.P.P., D.F.E., and M.S. co-ordinated Studies of Epide-
miology and Risk Factors in Cancer Heredity (SEARCH); M.K.B. provided data
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05427-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3166 | DOI: 10.1038/s41467-018-05427-7 | www.nature.com/naturecommunications 9
management support for BCAC; I.D.V., P.K., and M.M.C. co-ordinated E2C2 genotyping
and analysis; F.D. and J.P. co-ordinated analysis of UK Biobank genotyping data; The
following authors provided samples and/or phenotypic data: F.A., D.A., K.A., J.A., P.L.A.,
M.W.B., A.B., H.B., H.Br., L.B., D.D.B., B.B., J.C.-C., S.J.C., C.C., C.L.C., M.C., L.S.C., F.J.
C., A.C., L.C., J.De., J.A.D., S.C.D., A.B.E., P.A.F., B.L.F., L.F., M.M.G., G.G.G., E.L.G., C.
A.H., P.H., S.H., A.H., P.Hi., E.H., J.L.H., D.J.H., C.K., V.N.K., D.L., L.L.M., E.L., A.L., J.
L., J.Lo., L.L., A.M.M., A.M., R.L.M., M.M., R.N., H.O., I.O., G.O., C.P., J.P., L.P., J.Pr., T.
P., T.R.R., H.A.R., R.A.W.R., I.R., C.S., G.E.S., F.S., V.W.S., X.S., X.-O.S., M.C.S., A.J.S., E.
T., J.T., C.T., C.V., D.V.D.B., A.V., Z.W., N.W., H.M.J.W., S.J.W., A.W., L.X., Y.-B.X., H.
P.Y., and H.Y. All authors provided critical review of the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-05427-7.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
Tracy A. O’Mara 1, Dylan M. Glubb 1, Frederic Amant2, Daniela Annibali 2, Katie Ashton3,4,5,
John Attia 3,6, Paul L. Auer7,8, Matthias W. Beckmann9, Amanda Black10, Manjeet K. Bolla11,
Hiltrud Brauch 12,13,14, Hermann Brenner14,15,16, Louise Brinton10, Daniel D. Buchanan 17,18,19,20,
Barbara Burwinkel21,22, Jenny Chang-Claude23,24, Stephen J. Chanock10, Chu Chen25, Maxine M. Chen26,
Timothy H.T. Cheng27, Christine L. Clarke28, Mark Clendenning17,20, Linda S. Cook29,30, Fergus J. Couch31,
Angela Cox32, Marta Crous-Bous26,33, Kamila Czene34, Felix Day 35, Joe Dennis 11, Jeroen Depreeuw2,36,37,
Jennifer Anne Doherty38, Thilo Dörk39, Sean C. Dowdy40, Matthias Dürst41, Arif B. Ekici42,
Peter A. Fasching 9,43, Brooke L. Fridley44, Christine M. Friedenreich 30, Lin Fritschi45, Jenny Fung46,
Montserrat García-Closas10,47, Mia M. Gaudet48, Graham G. Giles18,49,50, Ellen L. Goode51, Maggie Gorman27,
Christopher A. Haiman52, Per Hall34,53, Susan E. Hankison33,54, Catherine S. Healey55, Alexander Hein 9,
Peter Hillemanns39, Shirley Hodgson56, Erling A. Hoivik57,58, Elizabeth G. Holliday3,6, John L. Hopper18,
David J. Hunter26,59, Angela Jones27, Camilla Krakstad57,58, Vessela N. Kristensen60,61,62,
Diether Lambrechts37,63, Loic Le Marchand64, Xiaolin Liang65, Annika Lindblom66, Jolanta Lissowska67,
Jirong Long68, Lingeng Lu 69, Anthony M. Magliocco70, Lynn Martin 71, Mark McEvoy6, Alfons Meindl72,
Kyriaki Michailidou 11,73, Roger L. Milne 18,49, Miriam Mints74, Grant W. Montgomery 1,46, Rami Nassir75,
Håkan Olsson76, Irene Orlow65, Geoffrey Otton77, Claire Palles27, John R.B. Perry35, Julian Peto78,
Loreall Pooler52, Jennifer Prescott33, Tony Proietto77, Timothy R. Rebbeck79,80, Harvey A. Risch69,
Peter A.W. Rogers81, Matthias Rübner82, Ingo Runnebaum41, Carlotta Sacerdote83,84, Gloria E. Sarto85,
Fredrick Schumacher86, Rodney J. Scott3,4,5,87, V. Wendy Setiawan52, Mitul Shah55, Xin Sheng52, Xiao-Ou Shu68,
Melissa C. Southey17,88, Anthony J. Swerdlow89,90, Emma Tham66,91, Jone Trovik57,58, Constance Turman26,
Jonathan P. Tyrer55, Celine Vachon92, David VanDen Berg52, Adriaan Vanderstichele93, Zhaoming Wang10,
Penelope M. Webb 94, Nicolas Wentzensen10, Henrica M.J. Werner57,58, Stacey J. Winham95, Alicja Wolk 96,
Lucy Xia52, Yong-Bing Xiang97, Hannah P. Yang10, Herbert Yu 64, Wei Zheng 68, Paul D.P. Pharoah 11,55,
Alison M. Dunning55, Peter Kraft26,59, Immaculata De Vivo26,33, Ian Tomlinson 27,71, Douglas F. Easton 11,55,
Amanda B. Spurdle1 & Deborah J. Thompson 11
1Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane 4006 QLD, Australia. 2Department of
Obstetrics and Gynecology, University Hospitals KU Leuven, University of Leuven, Division of Gynecologic Oncology, Leuven 3000, Belgium. 3John
Hunter Hospital, Hunter Medical Research Institute, Newcastle 2305 NSW, Australia. 4University of Newcastle, Centre for Information Based
Medicine, Callaghan 2308 NSW, Australia. 5University of Newcastle, Discipline of Medical Genetics, School of Biomedical Sciences and Pharmacy,
Faculty of Health, Callaghan 2308 NSW, Australia. 6University of Newcastle, Centre for Clinical Epidemiology and Biostatistics, School of Medicine
and Public Health, Callaghan 2308 NSW, Australia. 7Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle 98109 WA,
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05427-7
10 NATURE COMMUNICATIONS |  (2018) 9:3166 | DOI: 10.1038/s41467-018-05427-7 | www.nature.com/naturecommunications
USA. 8University of Wisconsin-Milwaukee, Zilber School of Public Health, Milwaukee 53205 WI, USA. 9Department of Gynecology and Obstetrics,
University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center ER-EMN, Erlangen 91054,
Germany. 10National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda 20892 MD, USA. 11Department of Public Health and
Primary Care, University of Cambridge, Centre for Cancer Genetic Epidemiology, Cambridge CB1 8RN, UK. 12Dr. Margarete Fischer-Bosch-Institute
of Clinical Pharmacology, Stuttgart 70376, Germany. 13University of Tübingen, Tübingen 72074, Germany. 14German Cancer Research Center
(DKFZ), German Cancer Consortium (DKTK), Heidelberg 69120, Germany. 15Division of Clinical Epidemiology and Aging Research, German Cancer
Research Center (DKFZ), Heidelberg 69120, Germany. 16Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National
Center for Tumor Diseases (NCT), Heidelberg 69120, Germany. 17Department of Clinical Pathology, The University of Melbourne, Melbourne 3010
VIC, Australia. 18The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health,
Melbourne 3010 VIC, Australia. 19Genetic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville 3010 VIC, Australia. 20Victorian
Comprehensive Cancer Centre, University of Melbourne Centre for Cancer Research, Parkville 3010 VIC, Australia. 21Department of Obstetrics and
Gynecology, University of Heidelberg, Heidelberg 69120, Germany. 22Molecular Epidemiology Group, C080, German Cancer Research Center
(DKFZ), Heidelberg 69120, Germany. 23Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
24University Medical Center Hamburg-Eppendorf, Cancer Epidemiology, University Cancer Center Hamburg (UCCH), Hamburg 20246, Germany.
25Epidemiology Program, Fred Hutchinson Cancer Research Center, Seattle 98109 WA, USA. 26Department of Epidemiology, Harvard T.H. Chan
School of Public Health, Boston 02115 MA, USA. 27University of Oxford, Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical
Research Centre, Oxford OX3 7BN, UK. 28University of Sydney, Westmead Institute for Medical Research, Sydney 2145 NSW, Australia.
29University of New Mexico, University of New Mexico Health Sciences Center, Albuquerque 87131 NM, USA. 30Department of Cancer
Epidemiology and Prevention Research, Alberta Health Services, Calgary T2N 4N2 AB, Canada. 31Department of Laboratory Medicine and
Pathology, Mayo Clinic, Rochester 55905 MN, USA. 32Department of Oncology and Metabolism, University of Shefﬁeld, Shefﬁeld Institute for
Nucleic Acids (SInFoNiA), Shefﬁeld S10 2TN, UK. 33Department of Medicine, Harvard Medical School, Channing Division of Network Medicine,
Brigham and Women’s Hospital, Boston 02115 MA, USA. 34Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm
171 65, Sweden. 35University of Cambridge, MRC Epidemiology Unit, School of Clinical Medicine, Cambridge CB2 0QQ, UK. 36VIB, Vesalius
Research Center, Leuven 3000, Belgium. 37Department of Human Genetics, University of Leuven, Laboratory for Translational Genetics, Leuven
3000, Belgium. 38Cancer Research Huntsman Cancer Institute Department of Population Health Sciences, University of Utah, Salt Lake City 84112
UT, USA. 39Gynaecology Research Unit, Hannover Medical School, Hannover 30625, Germany. 40Department of Obstetrics and Gynecology, Mayo
Clinic, Division of Gynecologic Oncology, Rochester 55905 MN, USA. 41Department of Gynaecology, Jena University Hospital - Friedrich Schiller
University, Jena 07743, Germany. 42Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Institute
of Human Genetics, University Hospital Erlangen, Erlangen 91054, Germany. 43Department of Medicine, University of California at Los Angeles,
David Geffen School of Medicine, Division of Hematology and Oncology, Los Angeles 90095 CA, USA. 44Department of Biostatistics, Kansas
University Medical Center, Kansas City 66160 KS, USA. 45Curtin University, School of Public Health, Perth 6102 WA, Australia. 46University of
Queensland, Institute for Molecular Bioscience, Brisbane 4072 QLD, Australia. 47Institute of Cancer Research, Division of Genetics and
Epidemiology, London SM2 5NG, UK. 48American Cancer Society, Epidemiology Research Program, Atlanta 30303 GA, USA. 49Cancer
Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne 3004 VIC, Australia. 50Department of Epidemiology and Preventive
Medicine, Monash University, Melbourne 3004 VIC, Australia. 51Department of Health Science Research, Mayo Clinic, Division of Epidemiology,
Rochester 55905 MN, USA. 52Department of Preventive Medicine, University of Southern California, Keck School of Medicine, Los Angeles 90033
CA, USA. 53Department of Oncology, South General Hospital, Stockholm 118 83, Sweden. 54Department of Biostatistics and Epidemiology,
University of Massachusetts, Amherst, Amherst 01003 MA, USA. 55Department of Oncology, University of Cambridge, Centre for Cancer Genetic
Epidemiology, Cambridge CB1 8RN, UK. 56Department of Clinical Genetics, St George’s, University of London, London SW17 0RE, UK.
57Department of Clinical Science, University of Bergen, Centre for Cancer Biomarkers, Bergen 5020, Norway. 58Department of Gynecology and
Obstetrics, Haukeland University Hospital, Bergen 5021, Norway. 59Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan
School of Public Health, Boston 02115 MA, USA. 60Department of Cancer Genetics, Oslo University Hospital, Radiumhospitalet, Institute for Cancer
Research, Oslo 0379, Norway. 61University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo 0450, Norway. 62Department of
Clinical Molecular Biology, University of Oslo, Oslo University Hospital, Oslo 0450, Norway. 63VIB, VIB Center for Cancer Biology, Leuven 3001,
Belgium. 64Epidemiology Program, University of Hawaii Cancer Center, Honolulu 96813 HI, USA. 65Department of Epidemiology and Biostatistics,
Memorial Sloan-Kettering Cancer Center, New York 10065 NY, USA. 66Department of Molecular Medicine and Surgery, Karolinska Institutet,
Stockholm 171 76, Sweden. 67Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Cancer Center-Oncology Institute,
Warsaw 02-034, Poland. 68Department of Medicine, Vanderbilt University School of Medicine, Division of Epidemiology, Vanderbilt Epidemiology
Center, Vanderbilt-Ingram Cancer Center, Nashville 37232 TN, USA. 69Chronic Disease Epidemiology, Yale School of Public Health, New Haven
06510 CT, USA. 70Department of Anatomic Pathology, Mofﬁtt Cancer Center and Research Institute, Tampa 33612 FL, USA. 71University of
Birmingham, Institute of Cancer and Genomic Sciences, Birmingham B15 2TT, UK. 72Department of Gynecology and Obstetrics, Ludwig-
Maximilians University of Munich, Munich 80336, Germany. 73Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of
Neurology and Genetics, Nicosia, Cyprus. 74Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm 171 76, Sweden.
75Department of Biochemistry and Molecular Medicine, University of California Davis, Davis 95817 CA, USA. 76Department of Cancer
Epidemiology, Clinical Sciences, Lund University, Lund 222 42, Sweden. 77University of Newcastle, School of Medicine and Public Health, Callaghan
2308 NSW, Australia. 78Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London
WC1E 7HT, UK. 79Harvard T.H. Chan School of Public Health, Boston 02115 MA, USA. 80Dana-Farber Cancer Institute, Boston 02115 MA, USA.
81Department of Obstetrics and Gynaecology, University of Melbourne, Royal Women’s Hospital, Gynaecology Research Centre, Parkville 3052
VIC, Australia. 82Department of Gynaecology and Obstetrics, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center
Erlangen-EMN, University Hospital Erlangen, Erlangen 91054, Germany. 83Center for Cancer Prevention (CPO-Peimonte), Turin 10126, Italy.
84Human Genetics Foundation (HuGeF), Turino 10126, Italy. 85Department of Obstetrics and Gynecology, University of Wisconsin, School of
Medicine and Public Health, Madison 53715 WI, USA. 86Department of Epidemiology and Biostatistics, Case Western Reserve University,
Cleveland 44106 OH, USA. 87John Hunter Hospital, Division of Molecular Medicine, Pathology North, Newcastle 2308 NSW, Australia. 88Monash
University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton 3168 VIC, Australia. 89Division of Genetics and Epidemiology,
The Institute of Cancer Research, London SM2 5NG, UK. 90Division of Breast Cancer Research, The Institute of Cancer Research, London SW7 3RP,
UK. 91Karolinska Institutet, Clinical Genetics, Stockholm 171 76, Sweden. 92Department of Health Sciences Research, Mayo Clinic, Rochester 55905
MN, USA. 93Department of Obstetrics and Gynaecology, University Hospitals Leuven, Division of Gynecologic Oncology, Leuven Cancer Institute,
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05427-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3166 | DOI: 10.1038/s41467-018-05427-7 | www.nature.com/naturecommunications 11
Leuven 3000, Belgium. 94Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane 4006 QLD, Australia.
95Department of Health Science Research, Mayo Clinic, Division of Biomedical Statistics and Informatics, Rochester 55905 MN, USA.
96Department of Environmental Medicine, Karolinska Institutet, Division of Nutritional Epidemiology, Stockholm 171 77, Sweden. 97Department of
Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, State Key Laboratory of Oncogene and
Related Genes, Shanghai, China. These authors contributed equally: Amanda B. Spurdle, Deborah J. Thompson.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05427-7
12 NATURE COMMUNICATIONS |  (2018) 9:3166 | DOI: 10.1038/s41467-018-05427-7 | www.nature.com/naturecommunications
